Mashukur Rahman, Resident Doctor at Bangladesh Medical University, Medical Officer at Directorate General of Health Services, shared a post on LinkedIn:
‘Is ‘Inoperable’ becoming an outdated term in Liver Oncology?
A few years ago, a diagnosis of high-risk, large-volume Hepatocellular Carcinoma (HCC) was often a terminal conversation.
The tumors were too big for surgery and too advanced for a transplant.
But the ‘Glass Ceiling’ of liver cancer treatment is finally breaking.
I recently reviewed a case that perfectly illustrates this shift. They used a ‘Double-Whammy’ approach:
- Systemic Immunotherapy: To prime the immune system and attack the cancer globally.
- Targeted Interventional Radiology (IR): Using precision strikes like TACE/TARE to kill the tumor from within.
The Result?
Complete Downstaging.
What was once a massive, life-threatening mass shrunk and stabilized to the point where the patient moved from ‘Palliative Care’ to ‘Curative Surgery’ eligibility.
The Lesson:
We are moving away from ‘Siloed Medicine.’ The future isn’t just a better drug or a better surgery—it’s the synergy between the Oncologist, the Interventional Radiologist, and the Surgeon.
Are you seeing Immunotherapy change your surgical ‘No’ into a ‘Yes’? Let’s discuss the latest protocols in the comments.”
More posts featuring Mashukur Rahman.